{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:43:18Z","timestamp":1791834198869,"version":"4.3.4"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/T032413\/1"],"award-info":[{"award-number":["MR\/T032413\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009033","name":"NHS Blood and Transplant","doi-asserted-by":"publisher","award":["WPA15-02"],"award-info":[{"award-number":["WPA15-02"]}],"id":[{"id":"10.13039\/100009033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002927","name":"CUH | Addenbrooke\u2019s Charitable Trust, Cambridge University Hospitals","doi-asserted-by":"publisher","award":["900239"],"award-info":[{"award-number":["900239"]}],"id":[{"id":"10.13039\/501100002927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["21543\/Z\/19\/Z"],"award-info":[{"award-number":["21543\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The unprecedented emergence and spread of SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic, underscores the need for diagnostic and therapeutic technologies that can be rapidly tailored to novel threats. Here, we show that site-specific RNA endonuclease XNAzymes \u2013 artificial catalysts composed of single-stranded synthetic xeno-nucleic acid oligonucleotides (in this case 2\u2019-deoxy-2\u2019-fluoro-\u03b2-D-arabino nucleic acid) \u2013 may be designed, synthesised and screened within days, enabling the discovery of a range of enzymes targeting SARS-CoV-2 ORF1ab, ORF7b, spike- and nucleocapsid-encoding RNA. Three of these are further engineered to self-assemble into a catalytic nanostructure with enhanced biostability. This XNA nanostructure is capable of cleaving genomic SARS-CoV-2 RNA under physiological conditions, and when transfected into cells inhibits infection with authentic SARS-CoV-2 virus by RNA knockdown. These results demonstrate the potential of XNAzymes to provide a platform for the rapid generation of antiviral reagents.<\/jats:p>","DOI":"10.1038\/s41467-022-34339-w","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T11:05:57Z","timestamp":1668596757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection"],"prefix":"10.1038","volume":"13","author":[{"given":"Pehu\u00e9n Pereyra","family":"Gerber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4216-4719","authenticated-orcid":false,"given":"Maria J.","family":"Donde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3318-1851","authenticated-orcid":false,"given":"Nicholas J.","family":"Matheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7684-1437","authenticated-orcid":false,"given":"Alexander I.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"34339_CR1","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","volume":"16","author":"JA Kulkarni","year":"2021","unstructured":"Kulkarni, J. A. et al. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 16, 630\u2013643 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"34339_CR2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"E De Clercq","year":"2016","unstructured":"De Clercq, E. & Li, G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29, 695\u2013747 (2016).","journal-title":"Clin. Microbiol. Rev."},{"key":"34339_CR3","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3389\/fbioe.2020.00916","volume":"8","author":"H Uludag","year":"2020","unstructured":"Uludag, H., Parent, K., Aliabadi, H. M. & Haddadi, A. Prospects for RNAi therapy of COVID-19. Front. Bioeng. Biotechnol. 8, 916 (2020).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"34339_CR4","doi-asserted-by":"publisher","first-page":"802766","DOI":"10.3389\/fchem.2021.802766","volume":"9","author":"S Hegde","year":"2021","unstructured":"Hegde, S., Tang, Z., Zhao, J. & Wang, J. Inhibition of SARS-CoV-2 by targeting conserved viral RNA structures and sequences. Front. Chem. 9, 802766 (2021).","journal-title":"Front. Chem."},{"key":"34339_CR5","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/j.ymthe.2021.05.004","volume":"29","author":"A Idris","year":"2021","unstructured":"Idris, A. et al. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol. Ther. 29, 2219\u20132226 (2021).","journal-title":"Mol. Ther."},{"key":"34339_CR6","doi-asserted-by":"publisher","first-page":"e0066321","DOI":"10.1128\/JVI.00663-21","volume":"95","author":"V Lulla","year":"2021","unstructured":"Lulla, V. et al. Targeting the conserved stem loop 2 motif in the SARS-CoV-2 genome. J. Virol. 95, e0066321 (2021).","journal-title":"J. Virol."},{"key":"34339_CR7","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1021\/acs.molpharmaceut.0c01239","volume":"18","author":"MI Sajid","year":"2021","unstructured":"Sajid, M. I. et al. siRNA therapeutics for the therapy of COVID-19 and other coronaviruses. Mol. Pharm. 18, 2105\u20132121 (2021).","journal-title":"Mol. Pharm."},{"key":"34339_CR8","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.7150\/ijbs.59151","volume":"17","author":"R Wu","year":"2021","unstructured":"Wu, R. & Luo, K. Q. Developing effective siRNAs to reduce the expression of key viral genes of COVID-19. Int. J. Biol. Sci. 17, 1521\u20131529 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"34339_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/nar\/gkab1248","volume":"50","author":"S Ambike","year":"2022","unstructured":"Ambike, S. et al. Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread. Nucleic Acids Res. 50, 333\u2013349 (2022).","journal-title":"Nucleic Acids Res."},{"key":"34339_CR10","doi-asserted-by":"publisher","first-page":"801870","DOI":"10.3389\/fbioe.2022.801870","volume":"10","author":"M Friedrich","year":"2022","unstructured":"Friedrich, M. et al. Selection and validation of siRNAs preventing uptake and replication of SARS-CoV-2. Front. Bioeng. Biotechnol. 10, 801870 (2022).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"34339_CR11","doi-asserted-by":"publisher","first-page":"e15298","DOI":"10.15252\/emmm.202115298","volume":"14","author":"YC Chang","year":"2022","unstructured":"Chang, Y. C. et al. A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant. EMBO Mol. Med. 14, e15298 (2022).","journal-title":"EMBO Mol. Med."},{"key":"34339_CR12","doi-asserted-by":"publisher","first-page":"745559","DOI":"10.3389\/fgeed.2021.745559","volume":"3","author":"HJE Baddeley","year":"2021","unstructured":"Baddeley, H. J. E. & Isalan, M. The application of CRISPR\/Cas systems for antiviral therapy. Front. Genome Ed. 3, 745559 (2021).","journal-title":"Front. Genome Ed."},{"key":"34339_CR13","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.cell.2020.04.020","volume":"181","author":"TR Abbott","year":"2020","unstructured":"Abbott, T. R. et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell 181, 865\u2013876 e812 (2020).","journal-title":"Cell"},{"key":"34339_CR14","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1073\/pnas.94.9.4262","volume":"94","author":"SW Santoro","year":"1997","unstructured":"Santoro, S. W. & Joyce, G. F. A general purpose RNA-cleaving DNA enzyme. Proc. Natl Acad. Sci. USA 94, 4262\u20134266 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"34339_CR15","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1517\/14712598.2015.1025048","volume":"15","author":"AA Fokina","year":"2015","unstructured":"Fokina, A. A., Stetsenko, D. A. & Fran\u00e7ois, J.-C. DNA enzymes as potential therapeutics: towards clinical application of 10-23 DNAzymes. Expert Opin. Biol. Ther. 15, 689\u2013711 (2015).","journal-title":"Expert Opin. Biol. Ther."},{"key":"34339_CR16","first-page":"325","volume":"52","author":"LQ Sun","year":"2000","unstructured":"Sun, L. Q., Cairns, M. J., Saravolac, E. G., Baker, A. & Gerlach, W. L. Catalytic nucleic acids: from lab to applications. Pharmacol. Rev. 52, 325\u2013347 (2000).","journal-title":"Pharmacol. Rev."},{"key":"34339_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0167-7799(90)90169-X","volume":"8","author":"JJ Rossi","year":"1990","unstructured":"Rossi, J. J. & Sarver, N. RNA enzymes (ribozymes) as antiviral therapeutic agents. Trends Biotechnol. 8, 179\u2013183 (1990).","journal-title":"Trends Biotechnol."},{"key":"34339_CR18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/jgm.1111","volume":"9","author":"S Wu","year":"2007","unstructured":"Wu, S. et al. An efficient RNA-cleaving DNA enzyme can specifically target the 5\u2019-untranslated region of severe acute respiratory syndrome associated coronavirus (SARS-CoV). J. Gene Med. 9, 1080\u20131086 (2007).","journal-title":"J. Gene Med."},{"key":"34339_CR19","doi-asserted-by":"publisher","first-page":"47987","DOI":"10.1074\/jbc.M300504200","volume":"278","author":"M Cieslak","year":"2003","unstructured":"Cieslak, M., Szymanski, J., Adamiak, R. W. & Cierniewski, C. S. Structural rearrangements of the 10-23 DNAzyme to beta 3 integrin subunit mRNA induced by cations and their relations to the catalytic activity. J. Biol. Chem. 278, 47987\u201347996 (2003).","journal-title":"J. Biol. Chem."},{"key":"34339_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bpj.2017.06.004","volume":"113","author":"J Victor","year":"2017","unstructured":"Victor, J., Steger, G. & Riesner, D. Inability of DNAzymes to cleave RNA in vivo is due to limited Mg2+ concentration in cells. Eur. Biophys. J. 113, 1\u201311 (2017).","journal-title":"Eur. Biophys. J."},{"key":"34339_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1089\/oli.2006.16.297","volume":"16","author":"L Rivory","year":"2006","unstructured":"Rivory, L. et al. The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity. Oligonucleotides 16, 297\u2013312 (2006).","journal-title":"Oligonucleotides"},{"key":"34339_CR22","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.1021\/ja100710j","volume":"132","author":"DD Young","year":"2010","unstructured":"Young, D. D., Lively, M. O. & Deiters, A. Activation and deactivation of DNAzyme and antisense function with light for the photochemical regulation of gene expression in mammalian cells. J. Am. Chem. Soc. 132, 6183\u20136193 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"34339_CR23","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1093\/nar\/gkm465","volume":"35","author":"A Goodchild","year":"2007","unstructured":"Goodchild, A. et al. Cytotoxic G-rich oligodeoxynucleotides: putative protein targets and required sequence motif. Nucleic Acids Res. 35, 4562\u20134572 (2007).","journal-title":"Nucleic Acids Res."},{"key":"34339_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.copbio.2021.11.004","volume":"74","author":"N Freund","year":"2021","unstructured":"Freund, N., Furst, M. & Holliger, P. New chemistries and enzymes for synthetic genetics. Curr. Opin. Biotechnol. 74, 129\u2013136 (2021).","journal-title":"Curr. Opin. Biotechnol."},{"key":"34339_CR25","doi-asserted-by":"publisher","first-page":"a032490","DOI":"10.1101\/cshperspect.a032490","volume":"11","author":"AI Taylor","year":"2019","unstructured":"Taylor, A. I., Houlihan, G. & Holliger, P. Beyond DNA and RNA: the expanding toolbox of synthetic genetics. Cold Spring Harb. Perspect. Biol. 11, a032490 (2019).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"34339_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cbpa.2019.06.007","volume":"52","author":"M Hollenstein","year":"2019","unstructured":"Hollenstein, M. Nucleic acid enzymes based on functionalized nucleosides. Curr. Opin. Chem. Biol. 52, 93\u2013101 (2019).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"34339_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41557-021-00645-x","volume":"13","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Nguyen, K., Spitale, R. C. & Chaput, J. C. A biologically stable DNAzyme that efficiently silences gene expression in cells. Nat. Chem. 13, 319\u2013326 (2021).","journal-title":"Nat. Chem."},{"key":"34339_CR28","doi-asserted-by":"publisher","first-page":"8957","DOI":"10.1021\/jacs.1c02664","volume":"143","author":"K Yang","year":"2021","unstructured":"Yang, K. & Chaput, J. C. REVEALR: a multicomponent XNAzyme-based nucleic acid detection system for SARS-CoV-2. J. Am. Chem. Soc. 143, 8957\u20138961 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"34339_CR29","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/nprot.2015.104","volume":"10","author":"AI Taylor","year":"2015","unstructured":"Taylor, A. I. & Holliger, P. Directed evolution of artificial enzymes (XNAzymes) from diverse repertoires of synthetic genetic polymers. Nat. Protoc. 10, 1625\u20131642 (2015).","journal-title":"Nat. Protoc."},{"key":"34339_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature13982","volume":"518","author":"AI Taylor","year":"2015","unstructured":"Taylor, A. I. et al. Catalysts from synthetic genetic polymers. Nature 518, 427\u2013430 (2015).","journal-title":"Nature"},{"key":"34339_CR31","doi-asserted-by":"publisher","unstructured":"Taylor, A. I., Wan, J. K., Donde, M. J., Peak-Chew, S.-Y. & Holliger, P. A modular XNAzyme that cleaves long, structured RNAs under physiological conditions enables allele-specific gene silencing in cells. Nat. Chem. https:\/\/doi.org\/10.1038\/s41557-022-01021-z (2022).","DOI":"10.1038\/s41557-022-01021-z"},{"key":"34339_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141\u2013154 (2021).","journal-title":"Nat. Rev. Microbiol"},{"key":"34339_CR33","unstructured":"WHO. COVID-19 dashboard. https:\/\/covid19.who.int\/ (2022)."},{"key":"34339_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409\u2013424 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"34339_CR35","doi-asserted-by":"publisher","unstructured":"Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. https:\/\/doi.org\/10.1038\/s41586-021-04389-z (2021).","DOI":"10.1038\/s41586-021-04389-z"},{"key":"34339_CR36","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1056\/NEJMe2034294","volume":"384","author":"DP Harrington","year":"2021","unstructured":"Harrington, D. P., Baden, L. R. & Hogan, J. W. A large, simple trial leading to complex questions. N. Engl. J. Med. 384, 576\u2013577 (2021).","journal-title":"N. Engl. J. Med"},{"key":"34339_CR37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/d41586-021-03701-1","volume":"600","author":"M Kozlov","year":"2021","unstructured":"Kozlov, M. Merck\u2019s COVID pill loses its lustre: what that means for the pandemic. Nature 600, 365 (2021).","journal-title":"Nature"},{"key":"34339_CR38","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1126\/science.abc6156","volume":"369","author":"NJ Matheson","year":"2020","unstructured":"Matheson, N. J. & Lehner, P. J. How does SARS-CoV-2 cause COVID-19. Science 369, 510\u2013511 (2020).","journal-title":"Science"},{"key":"34339_CR39","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/d41587-020-00005-z","volume":"38","author":"J Hodgson","year":"2020","unstructured":"Hodgson, J. The pandemic pipeline. Nat. Biotechnol. 38, 523\u2013532 (2020).","journal-title":"Nat. Biotechnol."},{"key":"34339_CR40","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","volume":"181","author":"D Kim","year":"2020","unstructured":"Kim, D. et al. The architecture of SARS-CoV-2 transcriptome. Cell 181, 914\u2013921 e910 (2020).","journal-title":"Cell"},{"key":"34339_CR41","unstructured":"National Centre for Biotechnology Information (NCBI). SARS-CoV-2 data. https:\/\/www.ncbi.nlm.nih.gov\/projects\/sviewer\/?id=NC_045512."},{"key":"34339_CR42","doi-asserted-by":"publisher","first-page":"587269","DOI":"10.3389\/fcimb.2020.587269","volume":"10","author":"MY Wang","year":"2020","unstructured":"Wang, M. Y. et al. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front. Cell Infect. Microbiol. 10, 587269 (2020).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"34339_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00292-w","volume":"6","author":"NC Kyriakidis","year":"2021","unstructured":"Kyriakidis, N. C., Lopez-Cortes, A., Gonzalez, E. V., Grimaldos, A. B. & Prado, E. O. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines 6, 28 (2021).","journal-title":"NPJ Vaccines"},{"key":"34339_CR44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1126\/science.1217622","volume":"336","author":"VB Pinheiro","year":"2012","unstructured":"Pinheiro, V. B. et al. Synthetic genetic polymers capable of heredity and evolution. Science 336, 341\u2013344 (2012).","journal-title":"Science"},{"key":"34339_CR45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1748-7188-6-26","volume":"6","author":"R Lorenz","year":"2011","unstructured":"Lorenz, R. et al. ViennaRNA package 2.0. Algorithms Mol. Biol. 6, 26 (2011).","journal-title":"Algorithms Mol. Biol."},{"key":"34339_CR46","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1006\/jmbi.1997.1036","volume":"269","author":"D Faulhammer","year":"1997","unstructured":"Faulhammer, D. & Famulok, M. Characterization and divalent metal-ion dependence of in vitro selected deoxyribozymes which cleave DNA\/RNA chimeric oligonucleotides. J. Mol. Biol. 269, 188\u2013202 (1997).","journal-title":"J. Mol. Biol."},{"key":"34339_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21953-3","volume":"12","author":"J Cubuk","year":"2021","unstructured":"Cubuk, J. et al. The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nat. Commun. 12, 1936 (2021).","journal-title":"Nat. Commun."},{"key":"34339_CR48","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/cbic.201600136","volume":"17","author":"AI Taylor","year":"2016","unstructured":"Taylor, A. I. et al. Nanostructures from synthetic genetic polymers. ChemBioChem 17, 1107\u20131110 (2016).","journal-title":"ChemBioChem"},{"key":"34339_CR49","doi-asserted-by":"publisher","first-page":"9410","DOI":"10.1039\/C8CC05721D","volume":"54","author":"HBD Thai","year":"2018","unstructured":"Thai, H. B. D. et al. Tetrahedral DNAzymes for enhanced intracellular gene-silencing activity. Chem. Commun. 54, 9410\u20139413 (2018).","journal-title":"Chem. Commun."},{"key":"34339_CR50","doi-asserted-by":"publisher","first-page":"e1010265","DOI":"10.1371\/journal.ppat.1010265","volume":"18","author":"PP Gerber","year":"2022","unstructured":"Gerber, P. P. et al. A protease-activatable luminescent biosensor and reporter cell line for authentic SARS-CoV-2 infection. PLoS Pathog. 18, e1010265 (2022).","journal-title":"PLoS Pathog."},{"key":"34339_CR51","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.omtn.2019.07.001","volume":"17","author":"M Takahashi","year":"2019","unstructured":"Takahashi, M. et al. Dual mechanisms of action of self-delivering, anti-HIV-1 FANA oligonucleotides as a potential new approach to HIV therapy. Mol. Ther. Nucleic Acids 17, 615\u2013625 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"34339_CR52","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41421-020-00197-3","volume":"6","author":"LK Zhou","year":"2020","unstructured":"Zhou, L. K. et al. Absorbed plant MIR2911 in honeysuckle decoction inhibits SARS-CoV-2 replication and accelerates the negative conversion of infected patients. Cell Disco. 6, 54 (2020).","journal-title":"Cell Disco."},{"key":"34339_CR53","doi-asserted-by":"publisher","unstructured":"Lee, J. Y. et al. Absolute quantitation of individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant differences. Elife https:\/\/doi.org\/10.7554\/eLife.74153 (2022).","DOI":"10.7554\/eLife.74153"},{"key":"34339_CR54","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1093\/nar\/gnh064","volume":"32","author":"MR Jakobsen","year":"2004","unstructured":"Jakobsen, M. R., Damgaard, C. K., Andersen, E. S., Podhajska, A. & Kjems, J. A genomic selection strategy to identify accessible and dimerization blocking targets in the 5\u2019-UTR of HIV-1 RNA. Nucleic Acids Res. 32, e67 (2004).","journal-title":"Nucleic Acids Res."},{"key":"34339_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-4-29","volume":"4","author":"MR Jakobsen","year":"2007","unstructured":"Jakobsen, M. R., Haasnoot, J., Wengel, J., Berkhout, B. & Kjems, J. Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites. Retrovirology 4, 29 (2007).","journal-title":"Retrovirology"},{"key":"34339_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88310-8","volume":"11","author":"IG Medeiros","year":"2021","unstructured":"Medeiros, I. G. et al. A small interfering RNA (siRNA) database for SARS-CoV-2. Sci. Rep. 11, 8849 (2021).","journal-title":"Sci. Rep."},{"key":"34339_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22785-x","volume":"12","author":"C Cao","year":"2021","unstructured":"Cao, C. et al. The architecture of the SARS-CoV-2 RNA genome inside virion. Nat. Commun. 12, 3917 (2021).","journal-title":"Nat. Commun."},{"key":"34339_CR58","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/nar\/gkab1273","volume":"50","author":"B Amirloo","year":"2022","unstructured":"Amirloo, B. et al. \u201cBind, cleave and leave\u201d: multiple turnover catalysis of RNA cleavage by bulge-loop inducing supramolecular conjugates. Nucleic Acids Res. 50, 651\u2013673 (2022).","journal-title":"Nucleic Acids Res."},{"key":"34339_CR59","doi-asserted-by":"publisher","unstructured":"Zhu, L., Yang, J., Ma, Y., Zhu, X. & Zhang, C. Aptamers entirely built from therapeutic nucleoside analogues for targeted cancer therapy. J. Am. Chem. Soc. https:\/\/doi.org\/10.1021\/jacs.1c09574 (2022).","DOI":"10.1021\/jacs.1c09574"},{"key":"34339_CR60","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1021\/acs.bioconjchem.8b00761","volume":"30","author":"S Benizri","year":"2019","unstructured":"Benizri, S. et al. Bioconjugated oligonucleotides: recent developments and therapeutic applications. Bioconjug. Chem. 30, 366\u2013383 (2019).","journal-title":"Bioconjug. Chem."},{"key":"34339_CR61","doi-asserted-by":"publisher","first-page":"758948","DOI":"10.3389\/fmicb.2021.758948","volume":"12","author":"J Khanali","year":"2021","unstructured":"Khanali, J., Azangou-Khyavy, M., Asaadi, Y., Jamalkhah, M. & Kiani, J. Nucleic acid-based treatments against COVID-19: potential efficacy of aptamers and siRNAs. Front. Microbiol. 12, 758948 (2021).","journal-title":"Front. Microbiol."},{"key":"34339_CR62","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1038\/mtna.2012.35","volume":"1","author":"N Souleimanian","year":"2012","unstructured":"Souleimanian, N. et al. Antisense 2\u2019-deoxy, 2\u2019-fluroarabino nucleic acids (2\u2019F-ANAs) oligonucleotides: in vitro gymnotic silencers of gene expression whose potency is enhanced by fatty acids. Mol. Ther. Nucleic Acids 1, e43 (2012).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"34339_CR63","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/eji.201646450","volume":"47","author":"H Garn","year":"2017","unstructured":"Garn, H. & Renz, H. GATA-3-specific DNAzyme - A novel approach for stratified asthma therapy. Eur. J. Immunol. 47, 22\u201330 (2017).","journal-title":"Eur. J. Immunol."},{"key":"34339_CR64","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1021\/nn2005574","volume":"5","author":"AS Walsh","year":"2011","unstructured":"Walsh, A. S., Yin, H., Erben, C. M., Wood, M. J. A. & Turberfield, A. J. DNA cage delivery to mammalian cells. ACS nano 5, 5427\u20135432 (2011).","journal-title":"ACS nano"},{"key":"34339_CR65","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V\u2019Kovski","year":"2021","unstructured":"V\u2019Kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155\u2013170 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"34339_CR66","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nbt.1543","volume":"27","author":"AA Khan","year":"2009","unstructured":"Khan, A. A. et al. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat. Biotechnol. 27, 549\u2013555 (2009).","journal-title":"Nat. Biotechnol."},{"key":"34339_CR67","doi-asserted-by":"publisher","first-page":"7371","DOI":"10.1128\/JVI.79.12.7371-7379.2005","volume":"79","author":"CS Sullivan","year":"2005","unstructured":"Sullivan, C. S. & Ganem, D. A virus-encoded inhibitor that blocks RNA interference in mammalian cells. J. Virol. 79, 7371\u20137379 (2005).","journal-title":"J. Virol."},{"key":"34339_CR68","doi-asserted-by":"publisher","first-page":"632290","DOI":"10.3389\/fmolb.2021.632290","volume":"8","author":"E Barberis","year":"2021","unstructured":"Barberis, E. et al. Circulating exosomes are strongly involved in SARS-CoV-2 infection. Front. Mol. Biosci. 8, 632290 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"34339_CR69","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/nar\/gki220","volume":"33","author":"EM Westerhout","year":"2005","unstructured":"Westerhout, E. M., Ooms, M., Vink, M., Das, A. T. & Berkhout, B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res. 33, 796\u2013804 (2005).","journal-title":"Nucleic Acids Res."},{"key":"34339_CR70","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1126\/science.abd3072","volume":"370","author":"JL Daly","year":"2020","unstructured":"Daly, J. L. et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science 370, 861\u2013865 (2020).","journal-title":"Science"},{"key":"34339_CR71","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/infdis\/jiaa507","volume":"222","author":"EI Patterson","year":"2020","unstructured":"Patterson, E. I. et al. Methods of inactivation of SARS-CoV-2 for downstream biological assays. J. Infect. Dis. 222, 1462\u20131467 (2020).","journal-title":"J. Infect. Dis."},{"key":"34339_CR72","doi-asserted-by":"publisher","unstructured":"Moore, S. C. et al. Amplicon-based detection and sequencing of SARS-CoV-2 in nasopharyngeal swabs from patients with COVID-19 and identification of deletions in the viral genome that encode proteins involved in interferon antagonism. Viruses https:\/\/doi.org\/10.3390\/v12101164 (2020).","DOI":"10.3390\/v12101164"},{"key":"34339_CR73","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34339-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34339-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34339-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T11:08:07Z","timestamp":1668596887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34339-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["34339"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-34339-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"assertion":[{"value":"22 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6716"}}